Trial Information
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Inclusion Criteria:
1. Subjects with a cytopathologically confirmed diagnosis of AML subjects with
refractory anemia with excess of blasts (RAEB) according to the WHO 2008
classification
2. ≥ 18 years
3. Written informed consent
Exclusion Criteria:
1. Subjects without a cytopathologically confirmed diagnosis of AML subjects with
refractory anemia with excess of blasts (RAEB) according to the WHO 2008
classification
2. < 18 years
3. Without written informed consent
Type of Study:
Observational
Study Design:
Observational Model: Case-Only
Outcome Measure:
Acceptance Criteria
Outcome Description:
The acceptance criteria based on lower level of the 95% CI of the positive or negative percent agreement for all markers.
Outcome Time Frame:
Sample taken at initial visit with no follow up (Day 1)
Safety Issue:
No
Principal Investigator
Martin Tallman, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
PROT-015
NCT ID:
NCT01463410
Start Date:
October 2011
Completion Date:
March 2013
Related Keywords:
- Acute Myeloid Leukemia (AML)
- Acute Promyelocytic Leukemia (APL)
- Refractory Anemia With Excess of Blasts (RAEB)
- Anemia
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Chromosome Aberrations
- Chromosome Disorders
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Leukemia, Promyelocytic, Acute
Name | Location |
Memorial Sloan Kettering Cancer Center |
New York, New York 10021 |
James Cancer Hospital |
Columbus, Ohio 43210 |